# Author Relationships With Industry and Other Entities (Comprehensive)—2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death Performance Measures

| **Committee Member** | **Employment**  | **Consultant** | **Speaker’s Bureau** | **Ownership/ Partnership/ Principal** | **Research** | **Institutional, Organizational, or Other Financial Benefit** | **Expert Witness** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sana Al-Khatib, Chair  | Duke Clinical Research Institute  | None | None | None | * AHRQ †
* NHLBI†
 | * Heart Rhythm Society Board of Trustees\*
 | None |
| Clyde W. Yancy, Co-Chair | Northwestern University, Feinberg School of Medicine | * None
 | None | None | * Patient Centered Outcomes Research Institute\*
 | * None
 | None |
| Lance B. Becker | North Shore University  | * Philips Medical\*
 | None | None | * Philips Medical†
* Benechill†
* Medtronic†
* Abbott Labs†
* ZOLL Medical†
* NIH†
* University of Pennslyvania Center for Resuscitation Science†
 | * University of Pennsylvania\*
* NIH-DSMB
* AHA\*
 | * 2011 Represented: Third Party Topic: Robert Rhone Murder Description: Expert witness for the prosecution in a case involving the murder of a citizen\*
 |
| Emelia J. Benjamin | Boston University  | * Nature Reviews Cardiology, Advisory Board\*
* European Heart Journal, International Editorial Board\*
* NHLBI- CARDIA Outside Safety & Monitoring Board\*
 | None | None | None | * Associate Editor/Editorial Board, Circulation†
* NIH/NHLBI†
 | None |
| Roger G. Carrillo | University of Miami Hospital  | * Sensomatic/TYCO
* Spectranetics†
 | * Biotronik
* Sorin Group
* St Jude Medical
* Medtronik
 | None | * St. Jude Medical
 | * St. Jude Medical\*
 | * 2013 Defendant: Lead Extraction Procedure\*
 |
| Justin A. Ezekowitz | Mazankowski Alberta Heart Institute | * Servier
* Astra-Zeneca
* Pfizer
* Abbott Labs
* Bristol-Meyers-Squibb
* Novartis
 | None | None | * Amgen
* United Health Foundation †
* AIHS grant: Alberta HEART†
* CIHR grant: AHF-EM†
* NIH\*
* CIHR grant: SODIUM-HF†
 | * Heart and Stroke Foundation Canada (member of research committee) \*
* Canadian Cardiovascular Society (Chair of data committee, member of committee (guidelines, quality indicators)\*
 | None |
| Gregg C. Fonarow | Ahmanson-UCLA Cardiomyopathy Center Division of Cardiology | * Amgen
* Bayer
* Boston Scientific
* Johnson & Johnson
* Medicines Company
* Medtronic
* Novartis†
* Takeda
 | None | None | * Gambro
* Medtronic
* NHLBI†
* NIH/NIAID†
* Novartis†
 | * ACCF/AHA Task Force on Data Standards\*
* ACCF/AHA Task Force on Performance Measures\*
* ACTION Registry GWTG Steering Committee Chair\*
* AHA Consumer Health Quality Coordinating Committee\*
* AHA Manuscript Oversight Committee\*
* GWTG Steering Committee (PRT)\*
* Medtronic- IMPROVE HF Steering Committee\*
 | None |
| Bharat K. Kantharia | University of Texas Medical School at Houston  | None | None | None | None | None | None |
| Monica Kleinman | Boston Children Hospital  | None | None | Arcadia Solutions\* | NIH† | * Progeria Research Foundation\*
* International Liaison Committee on Resuscitation (Co-Chair, 2015 Conference)\*
* AHA (Chair, ECC committee)\*
* Boston MedFlight (non-profit)\*
 | * 2014 Plaintiff Critical Care Transport, Maternal shock resulting in fetal injury and neonatal death.
* 2014 Defendant Pediatric Critical Care, IV infiltrate secondary to sodium bicarbonate administration.
 |
| Graham Nichol | University of Washington  | None | None | None | * Philips Medical, ZOLL Medical- Dynamic AED Registry
* ZOLL Medical- HART Pilot Study
* NHLBI- Mild hypothermia for resuscitated out-of-hospital cardiac arrest patients
* NHLBI- Randomized Trial of Hemofiltration After Resuscitation from Cardiac Arrest
* NIH-Resuscitation Outcomes Consortium
* Sotera Wireless
* Velomedix Inc-Velocity Pilot Study of Ultrafast Hypothermia in Patients with ST-elevation Myocardial Infarction
* Philips Medical-Washington Study of Ultrasound in Resuscitation
 | * Medic One Foundation\*
* Member, Western States Affiliate Board of Directors, AHA
* Novel method of tracking location of monitor/defibrillators in time and space\*
* Abiomed
 | None |
| Paul Varosy (10/8/2014) | VA Eastern Colorado Health Care System —Director of Cardiac Electrophysiology | None | None | None | * VA Office of Health Services Research and Development†
 | * AHA (Guest Editor, Circulation, Circulation Arrhythmia and Electrophysiology and Circulation Cardiovascular Quality and Outcomes)\*
* AMA (Section co-editor, Archives of Internal Medicine)\*
 | None |

This table represents all relationships of committee members with industry and other entities. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10,000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

According to the ACC/AHA, a person has a *relevant* relationship IF: a) The *relationship or interest* relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the *document*; or b) The *company/entity* (with whom the relationship exists) makes a drug, drug class, or device addressed in the *document*, or makes a competing drug or device addressed in the *document*; or c) The *person or a member of the person’s household*, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the *document*.

\*No financial relationship.

†Significant (greater than $5,000) relationship.

ACC indicates American College of Cardiology; Acute Heart Failure—Emergency Management, (AHF-EM); AHA, American Heart Association; AHRQ, Agency for Healthcare and Research Quality; AIHS, Alberta Innovates - Health Solutions; AMA, American Medical Association; CARDIA, Coronary Artery Risk Development in Young Adults; CIHR, Canadian Institutes of Health Research; DSMB , Data Safety Monitoring Board; GWTG, Get With The Guidelines; HART, Hypothermia Duration After Resuscitation Trial; IMPROVE-HF, Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting Study; NHLBI, National Heart Lung Blood Institute; NIH, National Institute of Health; PRT, Physician Round Table; SODIUM-HF, Study of Dietary Intervention Under 100 MMOL in Heart Failure; and VA, Veterans Affairs.